Zainab Arslan1, Hazel Webb2, Emma Ashton3, Becky Foxler2, Kjell Tullus2, Aoife Waters2, Detlef Bockenhauer2,4. 1. Department of Paediatric Nephrology, Great Ormond Street Hospital, London, UK. Zainab.arslan@nhs.net. 2. Department of Paediatric Nephrology, Great Ormond Street Hospital, London, UK. 3. NE Thames Regional Genetics Laboratory, GOSH NHS Foundation Trust, London, UK. 4. Department of Renal Medicine, University College London, London, UK.
Abstract
BACKGROUND: Primary steroid resistant nephrotic syndrome (SRNS) is thought to have either genetic or immune-mediated aetiology. Knowing which children to screen for genetic causes can be difficult. Several studies have described the prevalence of genetic causes of primary SRNS to be between 30 and 40%, but these may reflect a selection bias for genetic testing in children with congenital, infantile, syndromic or familial NS and thus may overestimate the true prevalence in a routine clinical setting. METHODS: Retrospective electronic patient record analysis was undertaken of all children with non-syndromic SRNS and presentation beyond the first year of life, followed at our centre between 2005 and 2020. RESULTS: Of the 49 children who met the inclusion criteria, 5 (10%) had causative variants identified, predominantly in NPHS2. None responded to immunosuppression. Of the 44 (90%) who had no genetic cause identified, 33 (75%) had complete or partial remission after commencing second-line immunosuppression and 67% of these had eGFR > 90 ml/min/1.73 m2 at last clinical follow-up. Of the children who did not respond to immunosuppression, 64% progressed to kidney failure. CONCLUSIONS: In our cohort of children with non-syndromic primary SRNS and presentation beyond the first year of life, we report a prevalence of detectable causative genetic variants of 10%. Those with identified genetic cause were significantly (p = 0.003) less likely to respond to immunosuppression and more likely (p = 0.026) to progress to chronic kidney disease. Understanding the genetics along with response to immunosuppression informs management in this cohort of patients and variant interpretation. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Primary steroid resistant nephrotic syndrome (SRNS) is thought to have either genetic or immune-mediated aetiology. Knowing which children to screen for genetic causes can be difficult. Several studies have described the prevalence of genetic causes of primary SRNS to be between 30 and 40%, but these may reflect a selection bias for genetic testing in children with congenital, infantile, syndromic or familial NS and thus may overestimate the true prevalence in a routine clinical setting. METHODS: Retrospective electronic patient record analysis was undertaken of all children with non-syndromic SRNS and presentation beyond the first year of life, followed at our centre between 2005 and 2020. RESULTS: Of the 49 children who met the inclusion criteria, 5 (10%) had causative variants identified, predominantly in NPHS2. None responded to immunosuppression. Of the 44 (90%) who had no genetic cause identified, 33 (75%) had complete or partial remission after commencing second-line immunosuppression and 67% of these had eGFR > 90 ml/min/1.73 m2 at last clinical follow-up. Of the children who did not respond to immunosuppression, 64% progressed to kidney failure. CONCLUSIONS: In our cohort of children with non-syndromic primary SRNS and presentation beyond the first year of life, we report a prevalence of detectable causative genetic variants of 10%. Those with identified genetic cause were significantly (p = 0.003) less likely to respond to immunosuppression and more likely (p = 0.026) to progress to chronic kidney disease. Understanding the genetics along with response to immunosuppression informs management in this cohort of patients and variant interpretation. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: Daniel P Gale; Andrew Mallett; Chirag Patel; Tam P Sneddon; Heidi L Rehm; Matthew G Sampson; Detlef Bockenhauer Journal: Nat Rev Nephrol Date: 2020-11 Impact factor: 28.314
Authors: Carolin E Sadowski; Svjetlana Lovric; Shazia Ashraf; Werner L Pabst; Heon Yung Gee; Stefan Kohl; Susanne Engelmann; Virginia Vega-Warner; Humphrey Fang; Jan Halbritter; Michael J Somers; Weizhen Tan; Shirlee Shril; Inès Fessi; Richard P Lifton; Detlef Bockenhauer; Sherif El-Desoky; Jameela A Kari; Martin Zenker; Markus J Kemper; Dominik Mueller; Hanan M Fathy; Neveen A Soliman; Friedhelm Hildebrandt Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121
Authors: Ethan S Sen; Philip Dean; Laura Yarram-Smith; Agnieszka Bierzynska; Geoff Woodward; Chris Buxton; Gemma Dennis; Gavin I Welsh; Maggie Williams; Moin A Saleem Journal: J Med Genet Date: 2017-08-05 Impact factor: 6.318
Authors: Jameela A Kari; Sherif M El-Desoky; Mamdooh Gari; Khalid Malik; Virginia Vega-Warner; Svjetlana Lovric; Detlef Bockenhauer Journal: Ann Saudi Med Date: 2013 Nov-Dec Impact factor: 1.526
Authors: Jennifer D Varner; Megan Chryst-Stangl; Christopher Imokhuede Esezobor; Adaobi Solarin; Guanghong Wu; Brandon Lane; Gentzon Hall; Asiri Abeyagunawardena; Ayo Matory; Tracy E Hunley; Jen Jar Lin; David Howell; Rasheed Gbadegesin Journal: Front Pediatr Date: 2018-10-22 Impact factor: 3.418
Authors: Brandon M Lane; Rachel Cason; Christopher Imokhuede Esezobor; Rasheed A Gbadegesin Journal: Front Pediatr Date: 2019-01-29 Impact factor: 3.418